Reserpine


Curated chemical-phenotype interactions from CTD
GO IDGO nameInteraction typeReference
GO:0002027 Regulation of heart rate Decreases phenotype PMID:8447839
GO:0003990 Acetylcholinesterase activity Increases phenotype PMID:28212939
GO:0005391 P-type sodium:potassium-exchanging transporter activity Affects phenotype PMID:28212939
GO:0006749 Glutathione metabolic process Affects phenotype PMID:28212939; PMID:28212939; PMID:33279466; PMID:33279466
GO:0006915 Apoptotic process Increases phenotype PMID:15659109
GO:0006979 Response to oxidative stress Increases phenotype PMID:14685008; PMID:14685008; PMID:16444668; PMID:19761039; PMID:20628966; PMID:15659109; PMID:16444668; PMID:19761039; PMID:20628966; PMID:17478054; PMID:18579341; PMID:19952499
GO:0007631 Feeding behavior Affects phenotype PMID:38229316
GO:0008217 Regulation of blood pressure Affects phenotype PMID:2996345; PMID:3011863; PMID:7391984
GO:0008219 Cell death Increases phenotype PMID:24743698; PMID:7380136
GO:0008283 Cell population proliferation Affects phenotype PMID:26114099; PMID:8545835
GO:0010286 Heat acclimation Increases phenotype PMID:29499192
GO:0010942 Positive regulation of cell death Increases phenotype PMID:9215992
GO:0016042 Lipid catabolic process Increases phenotype PMID:28212939; PMID:28212939; PMID:33279466; PMID:33279466
GO:0031987 Locomotion involved in locomotory behavior Decreases phenotype PMID:33279466
GO:0032964 Collagen biosynthetic process Increases phenotype PMID:39800144
GO:0034440 Lipid oxidation Increases phenotype PMID:39800144
GO:0035641 Locomotory exploration behavior Decreases phenotype PMID:28212939
GO:0042310 Vasoconstriction Increases phenotype PMID:1678717; PMID:2861275; PMID:3360262; PMID:5441791; PMID:7470747
GO:0042415 Norepinephrine metabolic process Affects phenotype PMID:28212939; PMID:28212939; PMID:33279466; PMID:33279466
GO:0042416 Dopamine biosynthetic process Decreases phenotype PMID:23206800
GO:0042417 Dopamine metabolic process Affects phenotype PMID:28212939; PMID:33279466; PMID:33279466
GO:0042428 Serotonin metabolic process Affects phenotype PMID:28212939; PMID:33279466; PMID:33279466
GO:0042756 Drinking behavior Affects phenotype PMID:38229316
GO:0043299 Leukocyte degranulation Increases phenotype PMID:16475147
GO:0046209 Nitric oxide metabolic process Affects phenotype PMID:28212939
GO:0046466 Membrane lipid catabolic process Increases phenotype PMID:14685008; PMID:14685008; PMID:16444668; PMID:19761039; PMID:20628966; PMID:16444668; PMID:19761039; PMID:20628966; PMID:19109989; PMID:21161603; PMID:21161603
GO:0050890 Cognition Affects phenotype PMID:38229316
GO:0061744 Motor behavior Affects phenotype PMID:38229316
GO:0061951 Establishment of protein localization to plasma membrane Increases phenotype PMID:30591588
GO:0070994 Detection of oxidative stress Increases phenotype PMID:28212939; PMID:38229316
DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.